NCT00109811View on ClinicalTrials.gov

Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

September 30, 2007

Conditions
Adenocarcinoma of the ProstateRecurrent Prostate Cancer
Interventions
BIOLOGICAL

PSA:154-163(155L) peptide vaccine

Given subcutaneously

BIOLOGICAL

incomplete Freund's adjuvant

Given subcutaneously

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

21201-1595

University of Maryland Greenebaum Cancer Center, Baltimore

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00109811 - Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer | Biotech Hunter | Biotech Hunter